Rahul Rao is a Senior Research Analyst at an undisclosed employer. He specializes in a diverse range of topics including finance, science, and healthcare, with a focus on pharmaceutical manufacturing, AI platforms, and materials science. Rahul's work has been featured in prominent publications such as Inverse, Popular Science, and Scientific American.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Rahul Rao's coverage suggests a deep interest in scientific developments, specifically within space exploration, astronomy, nuclear fusion, and science and technology. His articles often include data citations and expert commentary.
Given the scientific focus of his work, Rahul would likely be receptive to pitches that offer insights from credible experts within these fields. Pitches offering access to new research findings or exclusive interviews with leading scientists involved in cutting-edge projects related to space exploration or nuclear fusion could capture his attention.
As there is no specific geographic focus mentioned for Rahul's coverage, it appears he takes an international view on scientific advancements without being limited by location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Enjoy more free content and benefits by creating an account Saving articles to read later requires an IEEE Spectrum account
Kissht is up 86% in three months since listing. A 61% growth rate, 5% RoAA and a 2.1% GNPA, but credit costs remain above 8%. At 2.4x book, what exactly are investors paying for?
By: Rahul Rao
"We can't explicitly say that we are seeing a decrease in star formation because of M32. But it's right there, and it's definitely the most likely suspect."
By: Rahul Rao
With market-leading positions in clean air and shock absorbers, strong cash generation and a 94% ROCE, Tenneco Clean Air has built a profitable legacy business while investing in affordable premium suspension technologies such as CVSAe and DaVinci. The key question for investors is whether these newer technologies can scale beyond Mahindra and turn Tenneco from an ICE-era cash generator into a broader automotive technology play.
By: Rahul Rao
A 15-year supply agreement, dedicated manufacturing capacity, and a company emerging from its largest capex cycle. Is Yasho finally entering its operating leverage phase, or has the market already priced it in?
By: Rahul Rao
"This will reduce the microbial load and keep clothes and other soft surfaces clean, at least microbially, for astronaut health."
By: Rahul Rao
This firm is spinning off its high-growth data centre arm from its core real estate business, but execution risks and an 18-24 month timeline remain.
By: Rahul Rao
For much of the past decade, Shilpa Medicare invested ahead of its earnings, building capacity and capabilities that have taken years to translate into meaningful returns. The company’s net block increased from around Rs 558 crore in FY19 to more than Rs 1,400 crore by FY25. Meanwhile, asset turnover declined sharply, ROCE moved into single […]
By: Rahul Rao
US sterile injectables, PET radiopharma and CRDMO are reshaping Jubilant Pharmova’s earnings profile. The key question is whether the company can scale its new capacity fast enough to generate returns that justify the significant investment.
By: Rahul Rao
Thomas Cook India is demerging its profitable Sterling Holiday Resorts to eliminate its conglomerate discount, separating high-margin forex and travel from hospitality.
